MOBERG DERMA RIGHTS ISSUE FULLY SUBSCRIBED

Moberg Derma AB (publ) has completed the rights issue to existing shareholders decided on 24 February 2011. The new issue provides the company with MSEK 12.0.

Moberg Derma has during the period 3-17 March 2011, completed a rights issue of shares with preferential rights for existing shareholders. The issue was subscribed to approximately 31 percent of subscription rights and 69 percent without preferential rights. The issue is fully subscribed and adds Moberg Derma MSEK 12.0. Issue capital will be used for operating activities.

"The completed capital raise provides additional flexibility in addition to the previously secured credit facility of 50 MSEK", comments Peter Wolpert, CEO of Moberg Derma.

Through the rights issue will increase the number of shares of 414 508 shares. After the rights issue share capital amounts to 652 849.60 SEK divided into 6,528,496 shares.

For further information, please contact:
Peter Wolpert, President and CEO of Moberg Derma
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35
E-mail: peter.wolpert@mobergderma.se

About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers projects in the preclinical phase to approved and launched products. The company began operations at the Karolinska Institute in Stockholm in 2006. Moberg Derma is owned by institutional and private investors, Board and management. For further information, please visit: www.mobergderma.se

Tags: